Vivus, Meda, Deerfield Management Company L.P. deal

Vivus exercised its 2008 option and reacquired the royalty rights to Muse alprostadil and avanafil through the purchase of a Deerfield subsidiary for $27 million. Vivus also said its previously announced divestiture of all assets related to Muse to Meda will close by Nov. 19. Vivus will receive $22 million up front from Meda and is eligible for a $1.5 million milestone payment based on future sales (see BioCentury, April 7, 2008 & Oct. 11). ...